Orphan Drugs Should Be Rarer, Insurers Urge, Citing Price Increases

FDA can improve drug pricing by limiting the number of orphan designations, AHIP argues; worryingly for industry, the agency appears to be already thinking along similar lines.

FDA is again being pulled into the drug pricing debate, this time by insurance companies with a report suggests that drugmakers may be exploiting orphan drug designation for economic gain with the non-orphan use of these treatments.

According to the report by America's Health Insurance Plans (AHIP), drugs being used primarily for the treatment of non-orphan indications...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet